BCR-ABL1 fusion

Finally, the duplex FA-eLCR successfully detected the BCR/ABL1p210 transcripts in patients with chronic myeloid leukemia (CML) and monitored the change of transcripts during treatment, with 100 % concordance to reverse transcription-quantitative polymerase chain reaction, highlighting its high potential in the early diagnosis and minimal residual disease (MRD) monitoring of CML. This work presents a novel strategy to address nonspecific amplification in LCR and introduces a cost-effective, highly sensitive platform for molecular diagnosis in clinical setting.

P3, N=150, Recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog | Not yet recruiting --> Recruiting

PREPARE-ALL identifies twice as many relapses as clinicians and serves as a practical decision-support tool for early relapse triage and treatment planning, enabling timely therapeutic adjustments and improved outcomes in pediatric ALL.

Additionally, the development of new therapeutic approaches is examined as a forward-looking tactic to produce more profound and long-lasting molecular responses which include immune-based therapies, combinatorial approaches, and promising third-generation TKIs. This review aims to improve patient outcomes and identify future avenues in CML research by combining new information with existing knowledge.

BM fibrosis is a critical factor influencing the response to TKIs in CML patients. Lower grades of fibrosis correlate with higher response rates and better clinical outcomes, suggesting the importance of early intervention and tailored treatment approaches based on fibrosis grading.

Our findings indicate that CAPE could serve as an adjunctive therapy for CML against drug resistance caused by the T315I mutation through a mechanism that does not directly inhibit BCR-ABL1. This study underscores the promise of targeting mitochondrial metabolism as a novel approach for overcoming therapeutic resistance in CML.

Tyrosine kinase inhibitors restore the distribution of memory T cells in patients with chronic myeloid leukemia (CML), but T cell exhaustion remains an issue. This situation highlights the need for alternative activation strategies to enhance immunity.

Multidisciplinary methods are crucial for diagnosing CML blast crisis. Orelabatinib shows efficacy, and more research on personalized treatment is needed.

At the time of initial diagnosis, the patient presented with a primary tumor in the right thigh and extensive metastatic involvement affecting both lungs, pleura, mediastinum, pelvic cavity, and the right inguinal region, resulting in the classification of the case as high-risk. In addition to conventional multimodal therapy, early intervention using tyrosine kinase inhibitors was implemented, leading to the achievement of an early complete response.

In the present study, Imatinib-sensitive K-562S cells were subjected to CBD treatment (IC50: 17.69 μM) for 4 and 12 h, followed by RNA sequencing to identify differentially expressed genes (DEGs)...The results presented in this study validate the considerable potential of CBD to induce broad transcriptional and signalling alterations, related to immune modulation, apoptosis, and metabolic processes in K-562S cells. These findings provide novel insights into the therapeutic potential of CBD and lay the groundwork for further investigation into its precision applications in haematological malignancies.

In the second case, a previously undetected BCR-ABL1 fusion was identified in a relapsed AML patient, along with additional molecular lesions, underscoring the aggressive nature of the disease. Our findings support a systematic, multimodal screening strategy in patients with atypical presentations to ensure the timely detection of clinically actionable fusion events.

In this study, we employed molecular dynamics simulation to observe the synergistic interactions of BCR-ABL1 by the allosteric inhibitor asciminib and ATP competitive inhibitors nilotinib and ponatinib. Our study reveals the allosteric communication pathway between asciminib and ponatinib, providing more detailed insights into the effectiveness of combination therapy. These findings provide valuable insights into combination therapies, aiding in the rational use of medications and guiding the design of novel inhibitors.